Clinical trial · Observational
Long-term Follow-up and Quality of Life of Patients Treated With Anticancer Drugs
Non-interventional and Longitudinal Study to Evaluate a List of Anticancer Drugs Under Real Conditions of Use and Measure the Quality of Life of Patients Treated at Rafaël Institute
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Currently, aspects related to the effects of anticancer treatments and the quality of life of patients and their needs are still poorly documented at the Rafael Institute. Thus this study will meet a dual objective: (1) the establishment of a registry to collect data on the safety and effectiveness of innovative and expensive anticancer drugs when administered in real life and (2) a measurement quantitative quality of life of patients treated with these drugs.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
| Symptoms and Signs | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- overall survival
- timeFrame
- Until death, assessed up to 36 months
- description
- OS is defined as the time from the starting date of study drug to the date of death due to any cause.
- measure
- progression free survival
- timeFrame
- Until progression or death, assessed up to 36 months
- description
- PFS is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first.
- measure
- incidence of adverse events
- timeFrame
- up to 36 months
- description
- graded according to NCI CTCAE v5.0
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age equal to or greater than 18 years (adult) * Patients treated with an anticancer drug included in the list of innovative/expensive therapies (protocol appendix) * Patients benefiting from non-pharmacological treatment at the Rafael Institute * Who understands the French language Exclusion Criteria: * \< 18 years old * Patient deprived of liberty, under guardianship or unable to give consent
References
Publications (0)
Data not yet available